Physician profile
Daniel Mark Cooper
NPI 1154355816
$1,345.35
in general payments reported to CMS, 2019-2025
10 companies · $41.26 in 2025
The $41.26 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2022: $71.01 · 2023: $308 · 2024: $146 · 2025: $41.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acutus Medical, INC. | $779.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $149.07 | 2023-2025 | Tezspire, Airsupra |
| Amgen INC. | $124.99 | 2023 | Tezspire |
| Lilly USA, LLC | $88.53 | 2024 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $83.82 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.20 | 2022-2025 | Hyqvia |
| Scpharmaceuticals INC. | $24.17 | 2024 | |
| Pfizer INC. | $22.86 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.88 | 2024 | |
| Cashflow Solutions, LLC | $16.24 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.